<SEC-DOCUMENT>0001213900-25-081751.txt : 20250828
<SEC-HEADER>0001213900-25-081751.hdr.sgml : 20250828
<ACCEPTANCE-DATETIME>20250828161526
ACCESSION NUMBER:		0001213900-25-081751
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20250825
FILED AS OF DATE:		20250828
DATE AS OF CHANGE:		20250828

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ASCENTAGE PHARMA GROUP INTERNATIONAL
		CENTRAL INDEX KEY:			0002023311
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				000000000
		STATE OF INCORPORATION:			E9
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-42484
		FILM NUMBER:		251273636

	BUSINESS ADDRESS:	
		STREET 1:		68 XINQING ROAD
		STREET 2:		SUZHOU INDUSTRIAL PARK
		CITY:			SUZHOU , JIANGSU
		STATE:			F4
		ZIP:			00000
		BUSINESS PHONE:		86 512 8555 7777

	MAIL ADDRESS:	
		STREET 1:		68 XINQING ROAD
		STREET 2:		SUZHOU INDUSTRIAL PARK
		CITY:			SUZHOU , JIANGSU
		STATE:			F4
		ZIP:			00000
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>ea0254405-6k_ascentage.htm
<DESCRIPTION>FORM 6-K
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">



<!-- Field: Rule-Page --><DIV STYLE="width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>UNITED STATES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="text-transform: uppercase"><B>Washington,
D.C. 20549 </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="text-transform: uppercase"><B>Form
6-K</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Report of Foreign Private Issuer</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Pursuant to Rule 13a-16 or 15d-16</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>under the Securities Exchange Act of 1934</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">For the month of <B>August 2025</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Commission File Number: 001-42484</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>ASCENTAGE PHARMA GROUP INTERNATIONAL</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><I>(Translation of Registrant&rsquo;s name into
English)</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>68 Xinqing Road</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Suzhou Industrial Park</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Suzhou, Jiangsu</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>China</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">(Address of principal executive offices)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt">Indicate by check mark whether the registrant files or will
file annual reports under cover of Form 20-F or Form 40-F.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Form 20-F &#9746;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Form 40-F &#9744;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<!-- Field: Rule-Page --><DIV STYLE="width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>EXPLANATORY NOTE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On August 25, 2025, Ascentage
Pharma Group International issued a press release entitled &ldquo;Ascentage Pharma to Participate in Three Upcoming Investor Conferences
in September 2025&rdquo;. A copy of the press release is furnished as Exhibit 99.1 to this Report.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<!-- Field: Page; Sequence: 2; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>INDEX TO EXHIBITS</B></P>





<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 9%"><B>Exhibit <BR>
Number</B></TD>
    <TD STYLE="padding-bottom: 1.5pt; width: 1%">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1.5pt solid; width: 90%; vertical-align: bottom"><B>Exhibit Title</B></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD>99.1</TD>
    <TD>&nbsp;</TD>
    <TD><A HREF="ea025440501ex99-1_ascentage.htm">Press Release dated August 25, 2025</A></TD></TR>
  </TABLE>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 3; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SIGNATURE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 60%">&nbsp;</TD>
    <TD STYLE="width: 40%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>ASCENTAGE PHARMA GROUP INTERNATIONAL</B></FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date: August 28, 2025</FONT></TD>
    <TD STYLE="border-bottom: black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/ Dajun Yang</I></FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name: Dajun Yang</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:&nbsp;&nbsp;&nbsp;Chief Executive Officer</FONT></TD></TR>
  </TABLE>
<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 4; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>ea025440501ex99-1_ascentage.htm
<DESCRIPTION>PRESS RELEASE DATED AUGUST 25, 2025
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 99.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><IMG SRC="ex99-1_001.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Ascentage Pharma to Participate in Three Upcoming
Investor Conferences in September 2025</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">ROCKVILLE, Md. and SUZHOU, China, August 25, 2025
-- Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855) (&ldquo;<B>Ascentage Pharma</B>&rdquo; or the &ldquo;<B>Company</B>&rdquo;),
a global, commercial stage, integrated biopharmaceutical company engaged in the discovery, development and commercialization of novel,
differentiated therapies to address unmet medical needs in cancer, announced today that the Company's management will participate in the
following investor conferences in September 2025.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Citi's 2025 Biopharma Back to School: </B>Fireside
chat at 4:00 pm EDT on September 3</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Cantor Global Healthcare Conference 2025:
</B>Fireside chat at 2:45 pm EDT on September 4</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>H.C. Wainwright 27th Annual Global Investment
Conference: </B>Presentation at 1:30 pm EDT on September 10</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The live webcast of the Citi and Cantor events
can be accessed from the investors section of the Company&rsquo;s website at https://ir.ascentage.com/news-events/events. An archived
replay will be available for 30 days following the event.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>About Ascentage Pharma Group International</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Ascentage Pharma Group International (NASDAQ:
AAPG; HKEX: 6855) (&ldquo;<B>Ascentage Pharma</B>&rdquo; or the &ldquo;<B>Company</B>&rdquo;) is a global, commercial stage, integrated
biopharmaceutical company engaged in the discovery, development and commercialization of novel, differentiated therapies to address unmet
medical needs in cancer. The company has built a rich pipeline of innovative drug products and candidates that include inhibitors targeting
key proteins in the apoptotic pathway, such as Bcl-2 and MDM2-p53 and next-generation kinase inhibitors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company&rsquo;s first approved product, Olverembatinib,
is the first novel third-generation BCR-ABL1 inhibitor approved in China for the treatment of patients with CML in chronic phase (CML-CP)
with T315I mutations, CML in accelerated phase (CML-AP) with T315I mutations, and CML-CP that is resistant or intolerant to first and
second-generation TKIs. It is covered by the China National Reimbursement Drug List (NRDL). Ascentage Pharma is currently conducting an
FDA-cleared registrational Phase III trial, called POLARIS-2, of Olverembatinib for CML, as well as registrational Phase III trials for
patients with newly diagnosed Ph+ ALL, called POLARIS-1, and SDH-deficient GIST patients, called POLARIS-3.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company&rsquo;s second approved product, Lisaftoclax,
is a novel Bcl-2 inhibitor for the treatment of various hematologic malignancies. Lisaftoclax has been approved by China&rsquo;s National
Medical Products Administration (NMPA) for the treatment of adult patients with chronic lymphocytic leukemia/small lymphocytic lymphoma
(CLL/SLL) who have previously received at least one systemic therapy including Bruton&rsquo;s tyrosine kinase (BTK) inhibitors. The Company
is currently conducting four global registrational Phase III trials: the FDA-cleared GLORA study of Lisaftoclax in combination with BTK
inhibitors in patients with CLL/SLL previously treated with BTK inhibitors for more than 12 months with suboptimal response; the GLORA-2
study in patients with newly diagnosed CLL/SLL; the GLORA-3 study in newly diagnosed, elderly and unfit patients with AML; and the FDA-cleared
GLORA-4 study in patients with newly diagnosed HR MDS.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Leveraging its robust R&amp;D capabilities, Ascentage
Pharma has built a portfolio of global intellectual property rights and entered into global partnerships and other relationships with
numerous leading biotechnology and pharmaceutical companies, such as Takeda, AstraZeneca, Merck, Pfizer, and Innovent, in addition to
research and development relationships with leading research institutions, such as Dana-Farber Cancer Institute, Mayo Clinic, National
Cancer Institute and the University of Michigan. For more information, visit https://ascentage.com/</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B></B></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Forward-Looking Statements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This press release includes forward-looking statements
within the meaning of the Private Securities Litigation Reform Act of 1995 and Section 27A of the Securities Act of 1933, as amended,
and Section 21E of the Securities Exchange Act of 1934, as amended.&nbsp;All statements, other than statements of historical facts, contained
in this press release may be forward-looking statements, including statements that express Ascentage Pharma&rsquo;s opinions, expectations,
beliefs, plans, objectives, assumptions or projections regarding future events or future results of operations or financial condition.
These forward-looking statements are subject to a number of risks and uncertainties as discussed in Ascentage Pharma&rsquo;s filings with
the&nbsp;SEC, including those set forth in the sections titled &ldquo;Risk factors&rdquo; and &ldquo;Cautionary note regarding forward-looking
statements&rdquo; in its Annual Report on Form 20-F for the year ended December 31, 2024, filed with the SEC on April 16, 2025, the sections
headed &ldquo;Forward-looking Statements&rdquo; and &ldquo;Risk Factors&rdquo; in the prospectus of the Company for its Hong Kong initial
public offering dated October 16, 2019, and other filings with the SEC and/or The Stock Exchange of Hong Kong Limited it has made or it
makes from time to time that may cause actual results, levels of activity, performance or achievements to be materially different from
the information expressed or implied by these forward-looking statements. The forward-looking statements contained in this press release
do not constitute profit forecast by the Company&rsquo;s management.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As a result of these factors, you should not rely
on these forward-looking statements as predictions of future events. The forward-looking statements contained in this press release are
based on Ascentage Pharma&rsquo;s current expectations and beliefs concerning future developments and their potential effects and speak
only as of the date of such statements. Ascentage Pharma does not undertake any obligation to update or revise any forward-looking statements,
whether as a result of new information, future events or otherwise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Contacts</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Investor Relations:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B></B>Hogan Wan, Head of IR and Strategy</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Ascentage Pharma</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Hogan.Wan@ascentage.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">+86 512 85557777</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Stephanie Carrington</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">ICR Healthcare</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">AscentageIR@icrhealthcare.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">+1 (646) 277-1282</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Media Relations:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B></B>Jon Yu</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">ICR Healthcare</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">AscentagePR@icrhealthcare.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">+1 (646) 677-1855</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<!-- Field: Page; Sequence: 2; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>ex99-1_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex99-1_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" !5 .\# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#^_BBHS( 6
M&"2N!]<^G_ZJB:Z5"08Y?EV%F( 14D#[7WLP# R(8BB;Y4=HVDC2%Q+4*I!U
M713O545)QM+12VUY>6[Z+GYO[HN96YKKENUS7LKIM.[=DDFG=MI*VK1!(Y6>
M0$N55=Q"1,2!M+??V_.W'$<>]^5^7!!&7J?B+0_#]A=ZOKNHV&BZ78PR75WJ
MFJ7,-EIUI;Q,4DGNK^XD2U@2-@1(LLJ31D'?&",5^*7_  48_P""S?PR_93U
M74?@]\%]*L?C1^T%C[%>Z<DVH7W@/X=ZA>VT:V,7C%M"$U[XCUF[>ZMHM-\%
M:&5N+Z[9[>ZUO2+J&2./\;_'/P9_:'_:*M-*^-O_  5<_:G\3_!SP/XAC77?
M!O[/>B6J7?Q/U[0UF\Z5_"GP9LDN?#OPZTQS&UO#KWC:Q\0ZKI6Z,:C<P3,9
MC^R<+>"V=YQ@<OSKB&I'AW),UK.GE:JQJYGQ+G-G%U)Y%D-*G[:K3C%W]MB)
M83"T+QEB,11IIU)?AG&WCGP_PYB<RRC)91SW.,II2JYE453#9=PQE&CM#.L^
MG7E0A5[T<.\3BZNOLL-6DU$_I#^(W_!5[_@GO\,+ZZL?$_[37@34=0M99(9[
M/P(=8^)N)HC\T?F_#G3?%5HKJ,"1);B.2UEWVUXEM>07%O#XE8_\%T/^":&J
M7JV2_'/6M-9W,8N;WX7?$JVLT^;&Z:9?"\C6ZY&<SHA Y(&,5^+/PXU7]G3P
M^(K']CK_ ()H:;\7[FWE>VA^(WQWT#Q'\?\ Q-=2R.TD=XOARSM=8\+:5?%V
M<D^'KJ"PMU58YF@N8YX8O<[_ .(W_!1+3[%IK;]B'P/H>@HC&32-/_9*TUM/
MBMDR&C?39X;C4/*(#.Z;,DLQC_=E*_5:?@7PUA(RI8Z68X=SYX82MG?B+P/D
M>/KPI57A_;5,FHK-JF"J5)J+EA:^)KRHSE['VM3DG)?S_7^E=FV(JR=&GB<T
MPU%Q^M1X7\*_$'/LOP[G3=7V>&SNL\IPV94%33E2QN'ITZ6)II584X1G&+_?
M_P""G[<_[(/[03Q:=\(/VB?A?XVU>:401:!!XJL-/\4RS$X$,?A;6)-/\2RD
M@;U>'2Y(MA5O,^=,_51=D ZJ[EM@!,T;84$Y*%@N <@,P8X. 1S7\7_B_P#:
M ^&NO:A%X9_:?_X)_P#[/%[JT&)6U7PUX&UO]F7XJP$D3(VDZSI4>GZ^+N*-
MHI(9].D1& C9CABY^]_V2_VBM:TK6-"T;]E#]H/Q)XWTV>[@MKO]C;]L[Q-,
MOB4VD<L$>HO\#?VC;2/5OL=[;6%ZR>'_  CXPL-0&L3)<^??6+Q2R1?&<<>
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MO6MC#9ZW>>!;F#2O#_B'PG;:FMP;R6+PCJ::5>VKV/V>"1?$+W6]I(II@O\
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M36&G>'M/M84LV@O)KR\U)KB$0A)[C4]0NY;[4IY"QOY[FZ:=3NPWX]?M-_\
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.%%% !1110 4444 ?_]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
